Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology,Immunology,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1186/s40893-017-0026-2.pdf
Reference42 articles.
1. Pugliatti M. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700–22.
2. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528–32.
3. Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis-a quiet revolution. Nat Rev Neurol. 2015;11(3):134–42.
4. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
5. Montalban X. Review of methodological issues of clinical trials in multiple sclerosis. J Neurol Sci. 2011;311 Suppl 1:S35–42.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial;European Journal of Neurology;2021-11-25
2. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.;Multiple Sclerosis and Related Disorders;2021-06
3. Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients;Frontiers in Neurology;2021-03-05
4. Long-term outcome in multiple sclerosis patients treated with fingolimod;Multiple Sclerosis and Related Disorders;2020-10
5. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies;Multiple Sclerosis Journal;2019-11-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3